Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Caribbean. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Southern Cone. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Andean region. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Mesoamerican region. by Santiago Avila-Rios (3160959)

Subjects:

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the whole LAC region. by Santiago Avila-Rios (3160959)

Subjects:

Ts5 recognition by scorpion antivenom and predicted epitopes. by Felipe Cerni (3477902)

Purification of IgG anti-Ts5 antibodies. by Felipe Cerni (3477902)

ApoE, MMP-9, Claudin-5, and Occludin Protein Expression. by Lu Xu (386491)

2D-DIGE identifies Car3 as a protein with decreased expression in livers of high-fat diet fed mice treated with Niclosamide. by Sarah W. Renner (3947426)

Three-, bi- and mono-functional Vγ9Vδ2 T-cell subsets decrease in HIV+ patients. by Rita Casetti (608635)

Decreased H3K4me3 in Δ cells is not necessarily due to decreased RNA polymerase II loading () ChIP analysis of H3K4me3 and RNA pol II levels on the locus by Klaas W. Mulder (12134)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Overtrained mice show reduced signaling capacity of DLS mGluR1/5 in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Occurrences of <i>V</i>. <i>vulnificus</i> in Florida between 2008 and 2020. by Andrea J. Ayala (3120333)

Subjects: